Test Price
2,800 AED✅ Home Collection Available
ATP1A3 Gene Sequencing for Alternating Hemiplegia of Childhood Type 2 (AHC2) – Dubai, UAE
Executive Summary & Core Metrics
- ✔ 99.9% Diagnostic Sensitivity – ISO 9001:2015 certified, full-gene next‑generation sequencing (NGS) for ATP1A3.
- ✔ VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection – Available daily from 8 AM to 11 PM.
- ✔ Post‑Result Genetic Counselling – Complimentary telephone session with a consultant medical geneticist to review the report.
- ✔ Insurance & Direct Billing – Verify coverage via WhatsApp at +971 54 548 8731.
Test Overview & Methodology
This advanced NGS test sequences the entire ATP1A3 gene to detect pathogenic variants associated with Alternating Hemiplegia of Childhood type 2 (AHC2), a rare neurodevelopmental disorder. It provides a definitive molecular diagnosis, guiding tailored treatment and genetic counselling for affected families.
| Feature | Our NGS Test (AHC2) | Closest Alternative (Sanger Sequencing) |
|---|---|---|
| Precision | Full ATP1A3 gene – detects all variant types (point mutations, indels, copy number changes) | Limited to targeted known mutations only |
| Methodology | Next‑Generation Sequencing (NGS) with validated bioinformatics pipeline | Sanger sequencing of exon‑by‑exon (lower throughput) |
| Turnaround Time | 3–4 Weeks | 4–6 Weeks |
| Clinical Utility | Diagnostic, prognostic, and family screening ready | Often requires reflex to broader panel |
Physician Insight & Safety Protocols
“As a Consultant Medical Geneticist, I have witnessed the relief that a precise molecular diagnosis brings to families navigating the complexities of Alternating Hemiplegia of Childhood. An ATP1A3 positive result confirms the clinical suspicion and opens the door to targeted management strategies, including avoidance of precipitating factors and early intervention with appropriate therapies. However, genetic test results must always be integrated with the full clinical picture and never used as the sole basis for treatment decisions. I strongly recommend pre- and post-test genetic counselling to ensure families fully understand the implications.”
— Lina Osama Zaki Quteineh, Consultant Medical Genetics, DHA Registration ID: 9294403
Important Advisory
Genetic test results should be interpreted by a qualified medical geneticist or neurologist. Do not discontinue, start, or alter any prescribed medication or therapy without explicit guidance from the referring specialist. The test is a diagnostic aid, not an emergency treatment directive.
Exclusion Criteria & ER Red Flags
- Minors (<18 years) require a legal guardian to provide informed consent in compliance with Federal Decree-Law No. 4 of 2016 on Medical Liability.
- Individuals with uncontrolled acute neurological symptoms (e.g., prolonged seizures, coma) are not candidates for home collection – seek immediate hospital care.
- This test is a planned genetic investigation and is not designed for acute emergency diagnosis.
🚨 Emergency Red Flags: Sudden severe headache, loss of consciousness, stroke-like symptoms, or status epilepticus – proceed to the nearest emergency department immediately. This test does not replace emergency evaluation.
Patient FAQ & Clinical Guidance
1. What does the ATP1A3 genetic test diagnose and who needs it?
The ATP1A3 Genetic Test definitively diagnoses Alternating Hemiplegia of Childhood type 2 by detecting pathogenic mutations in the ATP1A3 gene, which is the primary cause of the disorder. It is indicated for children with recurrent episodes of hemiplegia, dystonia, or paroxysmal eye movement abnormalities, and for families seeking genetic confirmation and risk assessment.
2. How is the sample collected and what is the turnaround time?
A simple blood draw (whole blood in EDTA tube) or alternative specimens (extracted DNA, dried blood spot on FTA card) are collected via our VIP Mobile Phlebotomy service, available daily from 8 AM to 11 PM with temperature-controlled cold‑chain logistics. Results are reported within 3–4 weeks using validated next‑generation sequencing technology.
3. Is this genetic test covered by insurance in the UAE?
Most UAE health insurance plans cover medically necessary genetic testing when prescribed by a neurologist or paediatrician. Our team verifies coverage and handles direct billing via WhatsApp at +971 54 548 8731 before sample collection. We manage pre‑approvals to minimise out‑of‑pocket expenses.
UAE Regulatory & Data Privacy Adherence
Data Privacy: All personal data and genetic results are processed in strict compliance with Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL). Your health information is encrypted, stored within secure UAE servers, and never shared without explicit consent.
Health Information Governance: Our laboratory operations adhere to Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields, ensuring the highest standards of electronic health data security and confidentiality. The test is performed under the DHA Facility License Number 1143.
Clinical & Logistical Metadata
| Test Name | ATP1A3 Gene Sequencing (Alternating Hemiplegia of Childhood Type 2) |
| Price (AED) | 2,800 AED |
| Turnaround Time | 3–4 Weeks |
| Sample Type / Matrix | Whole Blood (EDTA tube), Extracted DNA, or Dried Blood Spot (FTA card) |
| Methodology Used | Next‑Generation Sequencing (NGS) with full gene coverage |
| ICD-10-CM Code | G24.3 (Alternating hemiplegia of childhood) |
| LOINC Code | 98995-9 (ATP1A3 gene full mutation analysis) |
| DHA Facility License & Laboratory Address | License: 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE – DNA Labs UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians